Newman Dignan Sheerar buys $1,776,772 stake in Amgen (AMGN)

Amgen (AMGN) : Newman Dignan Sheerar scooped up 195 additional shares in Amgen during the most recent quarter end , the firm said in a disclosure report filed with the SEC on Jul 8, 2016. The investment management firm now holds a total of 11,029 shares of Amgen which is valued at $1,776,772.Amgen makes up approximately 1.14% of Newman Dignan Sheerar’s portfolio.

Other Hedge Funds, Including , Osborn Rohs Williams Donohoe Ltd boosted its stake in AMGN in the latest quarter, The investment management firm added 292 additional shares and now holds a total of 23,153 shares of Amgen which is valued at $3,729,948. Amgen makes up approx 0.72% of Osborn Rohs Williams Donohoe Ltd’s portfolio.Cullinan Associates Inc boosted its stake in AMGN in the latest quarter, The investment management firm added 10,680 additional shares and now holds a total of 71,400 shares of Amgen which is valued at $11,015,592. Amgen makes up approx 0.90% of Cullinan Associates Inc’s portfolio.

Amgen closed down -1.44 points or -0.89% at $160.52 with 26,91,810 shares getting traded on Wednesday. Post opening the session at $162.64, the shares hit an intraday low of $160.31 and an intraday high of $162.66 and the price fluctuated in this range throughout the day.Shares ended Wednesday session in Red.

On the company’s financial health, Amgen reported $2.90 EPS for the quarter, beating the analyst consensus estimate by $ 0.29 according to the earnings call on Apr 28, 2016. Analyst had a consensus of $2.61. The company had revenue of $5527.00 million for the quarter, compared to analysts expectations of $5321.84 million. The company’s revenue was up 9.8% compared to the same quarter last year. During the same quarter in the previous year, the company posted $2.48 EPS.

Many Wall Street Analysts have commented on Amgen. Amgen was Initiated by Bernstein to “Mkt Perform” on Jun 29, 2016.

Amgen Inc. (Amgen) is a biotechnology company. The Company is engaged in discovering developing manufacturing and delivering human therapeutics. The Company’s sales and marketing forces are located in the United States and Europe. In the United States it sells its products to pharmaceutical wholesale distributors. The Company also markets certain products directly to consumers through direct-to-consumer print and television advertising as well as through the Internet. Outside the United States the Company sells its products to healthcare providers and/or pharmaceutical wholesale distributors. The Company’s products include Neulasta (pegfilgrastim)/NEUPOGEN (filgrastim) Enbrel (etanercept) XGEVA/Prolia (denosumab) ESAs (erythropoiesis-stimulating agents) Sensipar/Mimpara (cinacalcet) Kyprolis and Evolocumab among others.

Leave a Reply

Amgen - Is it time to Sell?

Top Brokerage Firms are advising their investors on Amgen. Subscribe to MoneyFlowIndex.Org Pre-Market Alerts, You will be the first to know the street buzz.